Published in Int J Radiat Oncol Biol Phys on March 01, 1979
Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer. Clin Cancer Res (2010) 1.45
Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein. Radiat Res (2009) 1.40
Radiosensitizers in cervical cancer. Cisplatin and beyond. Radiat Oncol (2006) 1.07
Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers. Gynecol Oncol (2013) 1.02
Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis. Int J Gynecol Cancer (2013) 0.89
Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study. J Transl Med (2012) 0.87
Progress in gynecologic cancer research: the Gynecologic Oncology Group experience. Semin Oncol (2008) 0.85
A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study. Cancer Chemother Pharmacol (2011) 0.84
Therapeutic Mechanisms of Treatment in Cervical and Vaginal Cancer. Oncol Hematol Rev (2012) 0.83
Molecular Strategies of Deoxynucleotide Triphosphate Supply Inhibition Used in the Treatment of Gynecologic Malignancies. Gynecol Obstet (Sunnyvale) (2011) 0.80
Concomitant radiochemotherapy of cervical cancer: is it justified to reduce the dosage of cisplatin? Strahlenther Onkol (2009) 0.79
Alcohol Abuse Decreases Pelvic Control and Survival in Cervical Cancer: An Opportunity of Lifestyle Intervention for Outcome Improvement. Am J Clin Oncol (2015) 0.77
Ribonucleotide reductase inhibitors: a new look at an old target for radiosensitization. Front Oncol (2012) 0.76
American Brachytherapy Task Group Report: A pooled analysis of clinical outcomes for high-dose-rate brachytherapy for cervical cancer. Brachytherapy (2017) 0.75
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med (1996) 5.56
Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer (1993) 2.96
Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol (1984) 2.25
Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol (1995) 2.17
Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol (1991) 1.83
Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J Clin Oncol (1994) 1.68
A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol (1989) 1.67
Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol (1998) 1.67
Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol (1994) 1.62
Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol (1985) 1.56
Second-look laparotomy in ovarian germ cell tumors: the gynecologic oncology group experience. Gynecol Oncol (1994) 1.55
A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer (1983) 1.54
Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol (1999) 1.53
The role of osteopenia in oral bone loss and periodontal disease. J Periodontol (1996) 1.51
Metastases to palm, sole, nailbed, nose, face and scalp from unsuspected carcinoma of the lung. Cancer (1969) 1.50
Second-look laparotomy and salvage therapy: a research modality only? Gynecol Oncol (1992) 1.45
Hormonal contraception and trophoblastic sequelae after hydatidiform mole (a Gynecologic Oncology Group Study) Am J Obstet Gynecol (1989) 1.44
A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol (1985) 1.43
Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol (1990) 1.42
Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of ip cisplatin and recombinant alpha-interferon. Gynecol Oncol (1992) 1.42
Diagnostic assessments in patients with invasive cancer of the cervix: a national patterns of care study of the American College of Surgeons. Gynecol Oncol (1996) 1.42
Monitoring the course of cervical carcinoma with the squamous cell carcinoma serum radioimmunoassay. Obstet Gynecol (1989) 1.41
Staging ovarian cancer diagnosed during laparoscopy: accuracy rather than immediacy. South Med J (1993) 1.39
Endometrial cancer, obesity, and body fat distribution. Cancer Res (1991) 1.33
Risk factors and recurrent patterns in Stage I endometrial cancer. Am J Obstet Gynecol (1985) 1.32
Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer (1991) 1.29
Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials. N Engl J Med (1982) 1.29
Labial agglutination secondary to a herpes simplex II infection. Am J Obstet Gynecol (1987) 1.28
Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol (1996) 1.27
Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol (1997) 1.26
Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol (1996) 1.25
A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer (1986) 1.25
Results and complications of operative staging in cervical cancer: experience of the Gynecologic Oncology Group. Gynecol Oncol (1980) 1.24
Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study). Am J Obstet Gynecol (1989) 1.22
A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol (1996) 1.22
The National Cancer Data Base report on malignant epithelial ovarian carcinoma in African-American women. Cancer (1997) 1.21
Adenocarcinoma of the cervix. I. Clinical evaluation and pathologic features. Am J Obstet Gynecol (1981) 1.18
Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group. Gynecol Oncol (2000) 1.13
Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Am J Obstet Gynecol (1992) 1.13
Human cervical intraepithelial neoplasia: fine structure of dysplasia and carcinoma in situ. Cancer Res (1968) 1.11
Squamous cell carcinoma of the uterine cervix. Patterns of thoracic metastases. Invest Radiol (1995) 1.10
The National Cancer Data Base report on endometrial carcinoma in African-American women. Cancer (1998) 1.08
Surgical management of radiation injury to the small intestine. Surg Gynecol Obstet (1976) 1.08
Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol (1999) 1.08
Radiation-associated gliomas: a report of four cases and analysis of postradiation tumors of the central nervous system. Neurosurgery (1985) 1.07
Malignant thymoma with metastases to the gastrointestinal tract and ovary: a case report and literature review. Am J Clin Oncol (2000) 1.06
Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study. Cancer Treat Rep (1986) 1.06
Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study. Am J Clin Oncol (2000) 1.06
Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol (2001) 1.06
A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol (1989) 1.06
Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol (2001) 1.06
c-myc amplification in ovarian cancer. Gynecol Oncol (1990) 1.05
Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol (1989) 1.05
A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol (2001) 1.04
The reirradiation of recurrent bronchogenic carcinoma with external beam irradiation. Am J Clin Oncol (1993) 1.04
Repair of the radiation-induced vaginal fistula utilizing the Martius technique. World J Surg (1986) 1.02
Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol (1998) 1.02
Rationale for using pathologic tumor dimensions and nodal status to subclassify surgically treated stage IB cervical cancer patients. Gynecol Oncol (1991) 1.02
A clinical and pathologic study of 30 cases of malignant mixed mullerian epithelial and mesenchymal ovarian tumors: a Gynecologic Oncology Group study. Gynecol Oncol (1984) 1.02
Phase II trial of etoposide in the management of advanced and recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group Study. Cancer Treat Rep (1987) 1.02
Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group. Gynecol Oncol (2000) 1.01
A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol (1994) 1.01
Cryosurgery of cervical intraepithelial neoplasia. Obstet Gynecol (1981) 1.00
Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol (2000) 0.99
Diagnosis and treatment of pulmonary metastases from cervical carcinoma. Gynecol Oncol (1990) 0.98
Pseudo-Meigs' syndrome with mucinous cystadenoma. Report of a case in which the effusions contained atypical cells. Obstet Gynecol (1967) 0.98
Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatin. Cancer (1989) 0.96
Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A Gynecologic Oncology Group Study (a final report). Cancer (1985) 0.96
Identification of prognostic factors and risk groups in patients found to have nodal metastasis at the time of radical hysterectomy for early-stage squamous carcinoma of the cervix. Gynecol Oncol (1989) 0.96
Prospective randomized trial of LLETZ versus laser ablation in patients with cervical intraepithelial neoplasia. Gynecol Oncol (1994) 0.96
Sinonasal undifferentiated carcinoma: a 10-year experience. Am J Otolaryngol (1996) 0.96
CA125 as a serum marker for poor prognosis in ovarian malignancies. Gynecol Oncol (1987) 0.95
Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol (1998) 0.95
Embryonal sarcoma of the liver in an adult treated with preoperative chemotherapy, radiation therapy, and hepatic lobectomy. Cancer (1992) 0.95
Treatment of adenocarcinoma of the endometrium at Memorial-James Ewing Hospitals, 1949-1965. Obstet Gynecol (1976) 0.95
Specific cytogenetic changes in ovarian cancer involving chromosomes 6 and 14. Cancer Res (1980) 0.95
Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol (1989) 0.94
Bilateral synchronous breast cancer: mode of detection and comparison of histologic features between the 2 breasts. Surgery (2000) 0.94
A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol (1994) 0.94
Complications of combined radical hysterectomy-postoperative radiation therapy in women with early stage cervical cancer. Gynecol Oncol (1989) 0.94
Treatment of advanced ovarian carcinoma in the elderly. Gynecol Oncol (1993) 0.93
A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma. Cancer (1983) 0.93
The National Cancer Data Base report on endometrial cancer. J Surg Oncol (1996) 0.93
Breast conservation radiation therapy technique for women with large breasts. Int J Radiat Oncol Biol Phys (1989) 0.93
Phase II evaluation of altretamine for advanced or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol (1996) 0.93
A phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study. Am J Clin Oncol (1993) 0.93
Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology Group. Gynecol Oncol (1999) 0.92
Transient radiation myelopathy (Lhermitte's sign) in patients with Hodgkin's disease treated by mantle irradiation. Int J Radiat Oncol Biol Phys (1980) 0.92
Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study. Gynecol Oncol (1999) 0.91
Combination chemotherapy with hydroxyurea, dacarbazine (DTIC), and etoposide in the treatment of uterine leiomyosarcoma: a Gynecologic Oncology Group study. Gynecol Oncol (1996) 0.91
Amonafide in patients with leiomyosarcoma of the uterus: a phase II Gynecologic Oncology Group study. Am J Clin Oncol (1998) 0.91
Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol (1989) 0.91
T lymphocytes infiltrating advanced grades of cervical neoplasia. CD8-positive cells are recruited to invasion. Cancer (1995) 0.91
Cisplatin and pentoxifylline in advanced or recurrent squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group. Gynecol Oncol (2000) 0.90
A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium. Gynecol Oncol (1996) 0.90